EU Boosts Africa's Vaccine Production Capacity with Significant Investment
Brussels – The European Union is making a substantial commitment to bolster vaccine manufacturing capabilities across Africa, investing hundreds of millions of euros through its Global Gateway strategy. This multi-pronged approach aims to reduce the continent's heavy reliance on imported vaccines and medicines, enhance health security, and promote equitable access to essential health products. Africa currently imports 99% of its vaccines and up to 90% of its medicines, a vulnerability starkly highlighted during the COVID-19 pandemic when the continent received less than 2% of global vaccine supplies [2].
Key initiatives under the "Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa" (MAV+) umbrella are driving this investment. A significant portion of the funding is directed towards BioNTech's mRNA vaccine manufacturing facility in Rwanda, with a €95 million package comprising an EU grant and an EIB credit facility [2, 4]. This facility is poised to become a cornerstone of Africa's emerging vaccine ecosystem, with the potential to produce mRNA vaccines for diseases critical to the continent, such as malaria, tuberculosis, HIV, and mpox [4].
Further strengthening the continent's biomanufacturing capacity, the European Investment Bank (EIB), European Commission, and the International Finance Corporation (IFC) are backing Biovac in South Africa to develop Africa's first end-to-end multi-vaccine manufacturing site [3, 10]. This project, representing Biovac's largest investment to date, includes a €75 million quasi-equity investment from the EIB Group and is expected to produce vaccines for cholera, polio, meningitis, and pneumonia [3, 10]. The facility is projected to be completed by 2028 and will also contribute to the local economy by creating over 340 skilled jobs [3].
The African Vaccines Manufacturing Accelerator (AVMA) is another critical component of the EU's strategy. The EU, its Member States, and European financial institutions have pledged over €750 million to the AVMA, which aims to purchase more than 800 million vaccine doses produced in Africa over the next decade [6, 7]. This initiative provides manufacturers with crucial demand assurance and financial support to offset high start-up costs, fostering the growth of at least four African vaccine manufacturers [6, 8].
These investments extend to bolstering regulatory capacities in Ghana, supporting local medicine production in Nigeria, and enhancing pharmaceutical sovereignty in Senegal [2]. The overarching goal is to create an enabling environment for the pharmaceutical industry in Africa, including training a skilled workforce and strengthening regulatory frameworks [6, 8]. By investing in local production, the EU aims to achieve a more resilient global health architecture and ensure that African countries can meet a greater proportion of their vaccine needs from within the continent, aligning with the African Union's ambition to produce 60% of its vaccines locally by 2040 [7, 11].
Key initiatives under the "Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa" (MAV+) umbrella are driving this investment. A significant portion of the funding is directed towards BioNTech's mRNA vaccine manufacturing facility in Rwanda, with a €95 million package comprising an EU grant and an EIB credit facility [2, 4]. This facility is poised to become a cornerstone of Africa's emerging vaccine ecosystem, with the potential to produce mRNA vaccines for diseases critical to the continent, such as malaria, tuberculosis, HIV, and mpox [4].
Further strengthening the continent's biomanufacturing capacity, the European Investment Bank (EIB), European Commission, and the International Finance Corporation (IFC) are backing Biovac in South Africa to develop Africa's first end-to-end multi-vaccine manufacturing site [3, 10]. This project, representing Biovac's largest investment to date, includes a €75 million quasi-equity investment from the EIB Group and is expected to produce vaccines for cholera, polio, meningitis, and pneumonia [3, 10]. The facility is projected to be completed by 2028 and will also contribute to the local economy by creating over 340 skilled jobs [3].
The African Vaccines Manufacturing Accelerator (AVMA) is another critical component of the EU's strategy. The EU, its Member States, and European financial institutions have pledged over €750 million to the AVMA, which aims to purchase more than 800 million vaccine doses produced in Africa over the next decade [6, 7]. This initiative provides manufacturers with crucial demand assurance and financial support to offset high start-up costs, fostering the growth of at least four African vaccine manufacturers [6, 8].
These investments extend to bolstering regulatory capacities in Ghana, supporting local medicine production in Nigeria, and enhancing pharmaceutical sovereignty in Senegal [2]. The overarching goal is to create an enabling environment for the pharmaceutical industry in Africa, including training a skilled workforce and strengthening regulatory frameworks [6, 8]. By investing in local production, the EU aims to achieve a more resilient global health architecture and ensure that African countries can meet a greater proportion of their vaccine needs from within the continent, aligning with the African Union's ambition to produce 60% of its vaccines locally by 2040 [7, 11].
This article and image are AI generated. For informational purposes only.